A comparison between gemcitabine-based combination chemotherapy and gemcitabine alone on advanced pancreatic cancer:a Meta-analysis in phase Ⅲ clinical trials / 中国癌症杂志
China Oncology
; (12)2006.
Article
en Zh
| WPRIM
| ID: wpr-546960
Biblioteca responsable:
WPRO
ABSTRACT
Background and purpose:Advanced pancreatic cancer is characteristic of poor treatment eff icacy and short survival time. Gemcitabine is considered as front-line therapy for advanced pancreatic cancer. Gemcitabine combinations have shown a favorable impact on survival. We compared gemcitabine-based combination cheme therapy and gemcitabine(GEM) alone in patients with advanced pancreatic cancer through Meta analysis in phase Ⅲ clinical trials. Methods:MEDLINE and EMBASE searches were supplemented by information from trial registers of phase Ⅲ randomized controlled trials(RCTs) for GEM-based combination therapy and GEM alone for advanced pancreatic cancer. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available RCTs. The Meta-analysis involved 6-months and 1-year survival rate and objective remission rate(ORR) . Results:The Meta-analysis included 20 RCTs. The result of our Meta-analysis showed that there was signifi cant improvement in the GEM combination group with regard to the 1-year survival rate(RR:0.87,95%:(0.78,0.96) ,P=0.008) . The other result of our meta-analysis showed no signifi cant difference between two groups. Conclusion:GEM-based combination therapy may be effective with regard to the survival rate compared with GEM alone.
Texto completo:
1
Base de datos:
WPRIM
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
Zh
Revista:
China Oncology
Año:
2006
Tipo del documento:
Article